ENTRY       D06886                      Drug
NAME        Natalizumab (USAN/INN);
            Natalizumab (genetical recombination) (JAN);
            Tysabri (TN)
PRODUCT     TYSABRI (Biogen)
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGFNIK DTYIHWVRQA PGQRLEWMGR IDPANGYTKY
            DPKFQGRVTI TADTSASTAY MELSSLRSED TAVYYCAREG YYGNYGVYAM DYWGQGTLVT
            VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
            QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP SCPAPEFLGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE
            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW
            QEGNVFSCSV MHEALHNHYT QKSLSLSLGK
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCKTSQDIN KYMAWYQQTP GKAPRLLIHY TSALQPGIPS
            RFSGSGSGRD YTFTISSLQP EDIATYYCLQ YDNLWTFGQG TKVEIKRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: H22-H96, H137-L213, H150-H206, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'137-L'213, H'150-H'206, H'264-H'324, H'370-H'428, L23-L-88, L133-L193, L'23-L'88, L'133-L'193)
  TYPE      Peptide
REMARK      Therapeutic category: 1190
            ATC code: L04AA23
            Product: D06886<JP/US>
EFFICACY    Immunosuppressant, Anti-integrin alpha 4 antibody
  DISEASE   Multiple sclerosis [DS:H01490]
            Crohn's disease [DS:H00286]
  TYPE      Monoclonal antibody
TARGET      ITGA4 (CD49D) [HSA:3676] [KO:K06483]
  PATHWAY   hsa04512(3676)  ECM-receptor interaction
            hsa04670(3676)  Leukocyte transendothelial migration
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA23 Natalizumab
                  D06886  Natalizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Central Nervous System Agents
              Multiple Sclerosis Agents
               Natalizumab
                D06886  Natalizumab (USAN/INN)
             Immunological Agents
              Immunological Agents, Other
               Selective Adhesion-Molecule Inhibitor
                Natalizumab
                 D06886  Natalizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               119  Miscellaneous
                1190  Miscellaneous
                 D06886  Natalizumab (USAN/INN); Natalizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: other families
               Integrins
                ITGA4 (CD49D)
                 D06886  Natalizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D06886
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D06886
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D06886
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D06886
DBLINKS     CAS: 189261-10-7
            PubChem: 49661786
            NIKKAJI: J2.128.102F
///
